Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

About this update from Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition. Severino brings more than 25 years of biopharmaceutical experience to Sarepta. Prior to Tessera, he served as Vice Chairman and President at AbbVie, where he was responsible for research and development and the corporate strategy office. During his tenure at AbbVie, he oversaw a rapid expansion of AbbVie’s pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precision medicine. Severino has made significant contributions to more than a dozen approved therapies including Rinvoq®, Skyrizi®, and Venclexta® and, under his leadership, AbbVie built leading franchises in hematologic oncology, immunology, and neuroscience. Over the course of his career, he has led the strategy behind the research, development, registration, and commercialization of novel agents across a wide range of therapeutic areas and built critical capabilities needed to lead in the era of rapidly advancing precision medicine. “It is a privilege to join Sarepta, the leader in precision genetic medicine for rare diseases, and a company driven by an extraordinary purpose: bringing innovative therapies, hope and possibility to patients and families facing serious and life-threatening diseases,” said Severino. “Throughout my career, I have focused on combining cutting edge science with drug development and commercialization expertise to improve the lives of patients. Sarepta’s unwavering commitment to patients and science resonates deeply with me, and I was very encouraged by the long-term data supporting our approved products, and the pre-clinical and clinical data from the siRNA pipeline programs and the potential for best-in-class treatments. I look forward to working with my new colleagues at Sarepta to continue to serve the Duchenne community and expand our reach.” “After a comprehensive search, which identified multiple experienced and attractive candidates, the Board is p...

View stock analysis, news, and events for Sarepta Therapeutics, Inc.